About Immorna
Immorna is a company based in Hangzhou (China) founded in 2019. Immorna has raised $115 million across 3 funding rounds from investors including Gates Foundation, Yuexiu Capital and Hillhouse. Immorna operates in a competitive market with competitors including Moderna, Strand Therapeutics, ReviR Therapeutics, Abogen Biosciences and Molecure, among others.
- Headquarter Hangzhou, China
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$115 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
Gates Foundation
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Immorna
Unlock access to complete
Funding Insights of Immorna
Immorna has successfully raised a total of $115M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immorna
Immorna has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, Yuexiu Capital and Hillhouse.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Yuexiu Capital is engaged in financial services and asset management.
|
Locked | Locked | Locked | |
|
Global private equity investments are managed with long-term focus.
|
Locked | Locked | Locked | |
|
VC fund investing in startups
|
Locked | Locked | Locked |
Investor details for Immorna
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immorna
Investment portfolio details for Immorna
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immorna
Detailed financials for Immorna
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immorna Comparisons
Peer comparison for Immorna
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immorna
Immorna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Strand Therapeutics, ReviR Therapeutics, Abogen Biosciences and Molecure, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
mRNA therapeutics platform is provided for multi-functional treatments.
|
|
| Locked | Locked | Locked |
RNA-based therapeutics for multiple diseases are developed using machine learning.
|
|
| Locked | Locked | Locked |
mRNA-based therapeutics are developed for cancer and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule drugs are developed for cancer and inflammatory diseases.
|
Detailed competitors of Immorna
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immorna
Complete news archive for Immorna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immorna
Immorna was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Immorna is headquartered in Hangzhou, China. It is registered at Hangzhou, Zhejiang, China.
Zihao Wang is the current CEO of Immorna.
Immorna is a funded company, having raised a total of $115M across 3 funding rounds to date.
Immorna was founded in 2019 in Hangzhou, China, within the biotechnology sector. mRNA-based therapeutics are developed by the company for cancer immunotherapy, infectious diseases, rare genetic diseases, and medical cosmetology. Delivery vehicles, including polymers and lipid nanoparticles, have been created for intramuscular, intravenous, and tissue-targeting applications. Operations focus on advancing a pipeline across these therapeutic areas.
Immorna's top competitors include Moderna, Strand Therapeutics and ReviR Therapeutics.
Immorna has 9 investors. Key investors include Gates Foundation, Yuexiu Capital, Hillhouse, Co-win Ventures, and China Growth Capital.